Literature DB >> 26392010

Critical issues in cancer vaccine trial design.

Guy T Clifton1, Holbrook E Kohrt2, George E Peoples3.   

Abstract

As the clinical experience with cancer vaccines and cancer immunotherapy increases, there are important lessons that can be learned from the successes and failures of past trials. Many lessons affect the design and conduct of clinical trials themselves. Appropriate patient selection, clinical trial design, immunologic monitoring, and appropriate endpoints are all essential to the efficiency and success of bringing cancer vaccines from conception to clinical use.
Copyright © 2015. Published by Elsevier Ltd.

Entities:  

Keywords:  Cancer vaccine; End points; Immunotherapy; Trial design

Mesh:

Substances:

Year:  2015        PMID: 26392010     DOI: 10.1016/j.vaccine.2015.09.019

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

Review 1.  Trial watch: Immune checkpoint blockers for cancer therapy.

Authors:  Claire Vanpouille-Box; Claire Lhuillier; Lucillia Bezu; Fernando Aranda; Takahiro Yamazaki; Oliver Kepp; Jitka Fucikova; Radek Spisek; Sandra Demaria; Silvia C Formenti; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-31       Impact factor: 8.110

Review 2.  Informatics for cancer immunotherapy.

Authors:  J Hammerbacher; A Snyder
Journal:  Ann Oncol       Date:  2017-12-01       Impact factor: 32.976

3.  ASO Author Reflections: The Tumor Lysate, Particle-Loaded, Dendritic Cell Vaccine for Advanced-Stage Melanoma: Reflection on Personalized Cancer Vaccination.

Authors:  Alexandra M Adams; Timothy J Vreeland; Guy T Clifton; George E Peoples
Journal:  Ann Surg Oncol       Date:  2021-02-26       Impact factor: 4.339

4.  Further insight into AE37 peptide vaccination in prostate cancer.

Authors:  Eleftheria A Anastasopoulou; Ioannis F Voutsas
Journal:  Future Sci OA       Date:  2017-05-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.